BridgeMD
New treatment option for Spondyloarthritis
Official title The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis
ClinicalTrials.gov ID: NCT05290363
What this study is testing
- What it's testing
- This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a multicentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in Spondyloarthritis patients attending the rheumatology department of Cochin, Saint-Antoine, Henri-Mondor hospitals (APHP) and Maison-Blanche Hospital (Reims).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age : Adults (\>18 years)
- Satisfying ASAS diagnostic criteria for SpA
- Patient has active disease, defined by the presence of active synovitis, tendinitis, or dactylitis or significant inflammatory pain of the spine...
- Informed consent signed
- Beneficiary of health insurance, except for the AME Only for patients of Group 1 Patient is naïve to biological therapies Only for patients of Group 2
See the full eligibility criteria
- Age : Adults (\>18 years)
- Satisfying ASAS diagnostic criteria for SpA
- Patient has active disease, defined by the presence of active synovitis, tendinitis, or dactylitis or significant inflammatory pain of the spine, judged by the examining clinician to be due to SpA.
- Informed consent signed
- Beneficiary of health insurance, except for the AME Only for patients of Group 1 Patient is naïve to biological therapies Only for patients of Group 2
- Patient is affected by peripheral SpA (ASAS criteria) or psoriatic arthritis, with inflammation of peripheral joints
- Patient requires aspiration, as part of standard care Non
- Patient is minor
- Patient is pregnant or breastfeeding
- Patient is immunocompromised
- Patient has received biological therapy with 2 or more biologics
- Patient is receiving corticosteroid treatment \> 10 mg per day
- Patient is under legal protection, curators, guardianship
- Patient refuses consent
- Previous history of alcoholism, drug addiction, psychological problems, severe concomitant conditions that could invalidate the patient's consent or limit the patient's compliance to the treatment protocol.
- Beneficiary of the AME Only for group 1
- Patient has received biological therapy
The study team makes the final eligibility decision.
Where it's taking place
- Créteil, France
- Paris, France
- Reims, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Créteil, France; Paris, France; Reims, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.